Structure-guided design of a selective BCL-XL inhibitor

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

(2012) D. Merino et al.   BLOOD

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Protein–protein interaction inhibitors get into the groove

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

(2011) P N Kelly et al.   CELL DEATH AND DIFFERENTIATION

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

(2011) Andreas Strasser et al.   EMBO JOURNAL

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets

(2011) Emma C. Josefsson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Integration, scaling, space-group assignment and post-refinement

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Bcl-2 Family Proteins as Therapeutic Targets

(2010) Peter E. Czabotar et al.   CURRENT PHARMACEUTICAL DESIGN

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

(2010) Jonathan B. Baell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Still embedded together binding to membranes regulates Bcl-2 protein interactions

(2010) B Leber et al.   ONCOGENE

Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands

(2009) Erinna F. Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cell Death

(2009) Richard S. Hotchkiss et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

(2008) V Labi et al.   CELL DEATH AND DIFFERENTIATION

Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands

(2008) M Kvansakul et al.   CELL DEATH AND DIFFERENTIATION

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

(2008) Erinna F. Lee et al.   JOURNAL OF CELL BIOLOGY

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

(2008) Cheol-Min Park et al.   JOURNAL OF MEDICINAL CHEMISTRY

Generation of a Set of Simple, Interpretable ADMET Rules of Thumb

(2008) M. Paul Gleeson   JOURNAL OF MEDICINAL CHEMISTRY

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax

(2008) J. I. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Plasticity Underpins Promiscuous Binding of the Prosurvival Protein A1

(2008) Callum Smits et al.   STRUCTURE